Maxim Reiterates Buy On IsoRay Following Barrow Study Results; Keeps $5 PT
In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on IsoRay Inc (NYSE:ISR) with a $5 price target, as the company announced results of a study of brain cancer patients treated with IsoRay’s Cesium-131 internal radiation (brachytherapy) cancer therapy.
Kolbert noted, “The company is taking the steps with studies like this one to build awareness around Cs-131 with leading medical institutions. The company is also hiring nine additional field reps this month to be located throughout the US. With Cs-131 approved for most solid tumors, broader adoption is key to market penetration. Management is seeing interest building in the treatment of brain cancers (meningiomas, brain metastases, and glioblastomas), lung cancer (NSCLC), gynecological cancer, prostate cancer, head and neck cancer, and liquid Cesium-131 in the GliaSite Radiation Therapy System, used to treat brain cancers.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 4.9% and a 41.4% success rate. Kolbert has a -7.5% average return when recommending ISR, and is ranked #752 out of 3388 analysts.